These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 24561132)

  • 1. Risk genes for schizophrenia: translational opportunities for drug discovery.
    Winchester CL; Pratt JA; Morris BJ
    Pharmacol Ther; 2014 Jul; 143(1):34-50. PubMed ID: 24561132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.
    Miyamoto S; Miyake N; Jarskog LF; Fleischhacker WW; Lieberman JA
    Mol Psychiatry; 2012 Dec; 17(12):1206-27. PubMed ID: 22584864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomics and epigenomics in novel schizophrenia drug discovery: translating animal models to clinical research and back.
    Bosia M; Pigoni A; Cavallaro R
    Expert Opin Drug Discov; 2015 Feb; 10(2):125-39. PubMed ID: 25345474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges and opportunities for the development of new antipsychotic drugs.
    Forray C; Buller R
    Biochem Pharmacol; 2017 Nov; 143():10-24. PubMed ID: 28522405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Support for the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia from exome sequencing in multiplex families.
    Timms AE; Dorschner MO; Wechsler J; Choi KY; Kirkwood R; Girirajan S; Baker C; Eichler EE; Korvatska O; Roche KW; Horwitz MS; Tsuang DW
    JAMA Psychiatry; 2013 Jun; 70(6):582-90. PubMed ID: 23553203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel treatment strategies for schizophrenia from improved understanding of genetic risk.
    Morris BJ; Pratt JA
    Clin Genet; 2014 Nov; 86(5):401-11. PubMed ID: 25142969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome-based drug discovery: prioritizing disease-susceptibility/disease-associated genes as novel drug targets for schizophrenia.
    Williams M
    Curr Opin Investig Drugs; 2003 Jan; 4(1):31-6. PubMed ID: 12625025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs.
    Miyamoto S; Duncan GE; Marx CE; Lieberman JA
    Mol Psychiatry; 2005 Jan; 10(1):79-104. PubMed ID: 15289815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in the genetics of schizophrenia: toward a network and pathway view for drug discovery.
    Collier DA; Eastwood BJ; Malki K; Mokrab Y
    Ann N Y Acad Sci; 2016 Feb; 1366(1):61-75. PubMed ID: 27111133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Commentary: genome-based CNS drug discovery: D-amino acid oxidase (DAAO) as a novel target for antipsychotic medications: progress and challenges.
    Williams M
    Biochem Pharmacol; 2009 Dec; 78(11):1360-5. PubMed ID: 19591808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Development of animal models, and drug discovery for schizophrenia based on the glutamate hypothesis].
    Nabeshima T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Nov; 30(5-6):195. PubMed ID: 21322311
    [No Abstract]   [Full Text] [Related]  

  • 13. Psychopharmacological treatment of schizophrenia: what do we have, and what could we get?
    Ellenbroek BA
    Neuropharmacology; 2012 Mar; 62(3):1371-80. PubMed ID: 21420988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of action of medicines for schizophrenia and bipolar illness: status and limitations.
    Scolnick EM
    Biol Psychiatry; 2006 Jun; 59(11):1039-45. PubMed ID: 16616720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Behavioral animal models of antipsychotic drug actions.
    Peleg-Raibstein D; Feldon J; Meyer U
    Handb Exp Pharmacol; 2012; (212):361-406. PubMed ID: 23129339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Critical review of mechanisms of action of second-generation antipsychotic drugs].
    Miyamoto S
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2006 Nov; 26(5-6):199-208. PubMed ID: 17240845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toward understanding genetic risk for differential antipsychotic response in individuals with schizophrenia.
    Arranz MJ; Munro JC
    Expert Rev Clin Pharmacol; 2011 May; 4(3):389-405. PubMed ID: 22114782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of NMDA receptor function as a treatment for schizophrenia.
    Cioffi CL
    Bioorg Med Chem Lett; 2013 Sep; 23(18):5034-44. PubMed ID: 23916256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress in defining the biological causes of schizophrenia.
    Pickard B
    Expert Rev Mol Med; 2011 Jul; 13():e25. PubMed ID: 21794196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evidence on the key role of the metabotrobic glutamatergic receptors in the pathogenesis of schizophrenia: a "breakthrough" in pharmacological treatment].
    Pannese R; Minichino A; Pignatelli M; Delle Chiaie R; Biondi M; Nicoletti F
    Riv Psichiatr; 2012; 47(2):149-69. PubMed ID: 22622251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.